Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine an optimal abatacept dosing regimen for the
treatment of active arthritis due to psoriatic arthritis in patients who have had a prior
inadequate response to disease-modifying antirheumatic drugs, including methotrexate and
tumor necrosis factor alpha-blockade compounds.